Glenmark Pharmaceuticals Recalls Carvedilol Tablets Over Nitrosamine Risk
Glenmark Pharmaceuticals recalled 4,800 bottles of Carvedilol Tablets on August 7, 2025. The recall stems from CGMP deviations leading to high levels of nitrosamine impurities. Consumers should stop using the product immediately and consult healthcare providers for guidance.
Product Details
The recalled product is Carvedilol Tablets, USP, 25 mg, in 500-count bottles. The National Drug Code (NDC) is 68462-165-05. These tablets were distributed nationwide in the USA.
The Hazard
The recall involves the presence of N-Nitroso Carvedilol I impurity above acceptable intake levels. This contamination poses a significant health risk to consumers.
What to Do
Consumers should stop using Carvedilol Tablets immediately. Contact Glenmark Pharmaceuticals Inc., USA, or consult your healthcare provider for further guidance.
Contact Information
For more information, call Glenmark Pharmaceuticals Inc. at 1-800-XXX-XXXX or visit their website. Additional details are available at the FDA's recall page.